• 1
    Bai R., Pettit G.R., Hamel E. (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol;39:19411949.
  • 2
    Schiff P.B., Fant J., Horwitz S.B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature;277:665667.
  • 3
    Owellen R.J., Owens A.H.J., Donigian D.W. (1972) The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun;47:685691.
  • 4
    Bollag D.M., McQueney P.A., Zhu J., Hensens O., Koupal L., Liesch J., Goetz M., Lazarides E., Woods C.M. (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res;55:23252333.
  • 5
    Lu Q., Luduena R.F. (1994) In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins. J Biol Chem;269:20412047.
  • 6
    Luduena R.F. (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol;178:207275.
  • 7
    Roach M.C., Boucher V.L., Walss C., Ravdin P.M., Luduena R.F. (1998) Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues. Cell Motil Cytoskeleton;39:273285.
  • 8
    Khan I.A., Luduena R.F. (2003) Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Invest New Drugs;21:313.
  • 9
    Banerjee A., Luduena R.F. (1992) Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J Biol Chem;267:1333513339.
  • 10
    Schwarz P.M., Luduena R.F. (2002) Interaction of nocodazole with tubulin isotypes. Drug Dev Res;55:9196.
  • 11
    Katsetos C.D., Legido A., Perentes E., Mork S.J. (2003) Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol;18:851866.
  • 12
    Katsetos C.D., Kontogeorgos G., Geddes J.F., Herman M.M., Tsimara-Papastamatiou H., Yu Y., Sakkas L.I., Tsokos M., Patchefsky A.S., Ehya H., Cooper H.S., Provencio J., Spano A.J., Frankfurter A. (2000) Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med;124:535544.
  • 13
    Scott C.A., Walker C.C., Neal D.A., Harper C.E., Bloodgood R.A., Somers K.D., Mills S.E., Rebhun L.I., Levine P.A. (1990) Beta-tubulin epitope expression in normal and malignant epithelial cells. Arch Otolaryngol Head Neck Surg;116:583589.
  • 14
    Ravelli R.B., Gigant B., Curmi P.A., Jourdain I., Lachkar S., Sobel A., Knossow M. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature;428:198202.
  • 15
    Gigant B., Wang C., Ravelli R.B., Roussi F., Steinmetz M.O., Curmi P.A., Sobel A., Knossow M. (2005) Structural basis for the regulation of tubulin by vinblastine. Nature;435:519522.
  • 16
    Nogales E., Wolf S.G., Khan I.A., Luduena R.F., Downing K.H. (1995) Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature;375:424427.
  • 17
    Huzil J.T., Luduena R.F., Tuszynski J. (2006) Comparative modelling of human beta-tubulin isotypes and implications for drug binding. Nanotechnology;17:S90S100.
  • 18
    Laclette J.P., Guerra G., Zetina C. (1980) Inhibition of tubulin polymerization by mebendazole. Biochem Biophys Res Commun;92:417423.
  • 19
    Tahir S.K., Kovar P., Rosenberg S.H., Ng S.C. (2000) Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. BioTechniques;29:156160.
  • 20
    Russell G.J., Lacey E. (1995) Inhibition of [3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem Mol Biol Int;35:11531159.
  • 21
    Hoebeke J., Van Nijen G., De Brabander M. (1976) Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. Biochem Biophys Res Commun;69:319324.
  • 22
    Lindahl E., Hess B., Van Der Spoel D. (2001) GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model;7:306317.
  • 23
    Brooks B.R., Brooks C.L. 3rd, Mackerell A.D. Jr, Nilsson L., Petrella R.J., Roux B., Won Y. et al. (2009) CHARMM: the biomolecular simulation program. J Comput Chem;30:15451614.
  • 24
    Wu G., Robertson D.H., Brooks C.L., Vieth M. (2003) Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem;24:15491562.
  • 25
    Dumont R., Brossi A., Chignell C.F., Quinn F.R., Suffness M. (1987) A novel synthesis of colchicide and analogues from thiocolchicine and congeners: reevaluation of colchicide as a potential antitumor agent. J Med Chem;30:732735.
  • 26
    Bartusik D., Tomanek B., Lattova E., Perreault H., Tuszynski J., Fallone G. (2009) The efficacy of new colchicine derivatives and viability of the T-Lymphoblastoid cells in three-dimensional culture using 19F MRI and HPLC-UV ex vivo. Bioorg Chem;37:193201.
  • 27
    Fellous A., Francon J., Lennon A.M., Nunez J. (1977) Microtubule assembly in vitro. Purification of assembly-promoting factors. Eur J Biochem;78:167174.
  • 28
    Banerjee A., Roach M.C., Wall K.A., Lopata M.A., Cleveland D.W., Luduena R.F. (1988) A monoclonal antibody against the type II isotype of beta-tubulin. Preparation of isotypically altered tubulin. J Biol Chem;263:30293034.
  • 29
    Lowe J., Li H., Downing K.H., Nogales E. (2001) Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol;313:10451057.
  • 30
    Brossi A., Yeh H.J., Chrzanowska M., Wolff J., Hamel E., Lin C.M., Quin F., Suffness M., Silverton J. (1988) Colchicine and its analogues: recent findings. Med Res Rev;8:7794.
  • 31
    Sun L., Hamel E., Lin C.M., Hastie S.B., Pyluck A., Lee K.H. (1993) Antitumor agents. 141. Synthesis and biological evaluation of novel thiocolchicine analogs: N-acyl-, N-aroyl-, and N-(substituted benzyl)deacetylthiocolchicines as potent cytotoxic and antimitotic compounds. J Med Chem;36:14741479.
  • 32
    Ferrari A.M., Degliesposti G., Sgobba M., Rastelli G. (2007) Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. Bioorg Med Chem;15:78657877.
  • 33
    Cucchiarelli V., Hiser L., Smith H., Frankfurter A., Spano A., Correia J.J., Lobert S. (2008) Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas. Cell Motil Cytoskeleton;65:675685.
  • 34
    Kavallaris M., Kuo D.Y., Burkhart C.A., Regl D.L., Norris M.D., Haber M., Horwitz S.B. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest;100:12821293.
  • 35
    Tommasi S., Mangia A., Lacalamita R., Bellizzi A., Fedele V., Chiriatti A., Thomssen C., Kendzierski N., Latorre A., Lorusso V., Schittulli F., Zito F., Kavallaris M., Paradiso A. (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer;120:20782085.
  • 36
    Banerjee A. (2002) Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun;293:598601.
  • 37
    Derry W.B., Wilson L., Khan I.A., Luduena R.F., Jordan M.A. (1997) Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry;36:35543562.
  • 38
    Burgoyne R.D., Cambray-Deakin M.A., Lewis S.A., Sarkar S., Cowan N.J. (1998) Differential distribution of beta-tubulin isotypes in cerebellum. EMBO J;7:23112319.
  • 39
    Ferlini C., Raspaglio G., Mozzetti S., Cicchillitti L., Filippetti F., Gallo D., Fattorusso C., Campiani G., Scambia G. (2005) The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res;65:23972405.
  • 40
    Luduena R.F., Prasad V., Roach M.C., Lacey E. (1998) The interaction of phomopsin A with bovine brain tubulin. Arch Biochem Biophys;272:3238.
  • 41
    Luduena R.F., Roach M.C., Prasad V., Chaudhuri A.R., Tomita I., Mizuhashi F., Murata K. (1995) Interaction of bovine brain tubulin with the 4(1H)-pyrizinone derivative IKP104, an antimitotic drug with a complex set of effects on the conformational stability of the tubulin molecule. Biochemistry;34:1575115759.
  • 42
    Schwarz P.M., Liggins J.R., Luduena R.F. (1998) Beta-tubulin isotypes purified from bovine brain have different relative stabilities. Biochemistry;37:46874692.
  • 43
    Chaudhuri A.R., Tomita I., Mizuhashi F., Murata K., Luduena R.F. (1998) Tubulin stability and decay: mediation by two distinct classes of IKP104-binding sites. J Protein Chem;17:303309.
  • 44
    Chaudhuri A.R., Seetharamalu P., Schwarz P.M., Hausheer F.H., Luduena R.F. (2000) The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach. J Mol Biol;303:679692.
  • 45
    Carles G., Braguer D., Dumontet C., Bourgarel V., Goncalves A., Sarrazin M., Rognoni J.B., Briand C. (1999) Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer;80:11621168.
  • 46
    Dozier J.H., Hiser L., Davis J.A., Thomas N.S., Tucci M.A., Benghuzzi H.A., Frankfurter A., Correia J.J., Lobert S. (2003) Beta class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res;5:R157R169.
  • 47
    Gan P.P., Pasquier E., Kavallaris M. (2007) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res;67:93569363.
  • 48
    Ranganathan S., Dexter D.W., Benetatos C.A., Chapman A.E., Tew K.D., Hudes G.R. (1996) Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res;56:25842589.